跳转至内容
Merck
CN

855987

D -缬氨酸

≥98%, for peptide synthesis

别名:

D-α-氨基异戊酸, D-2-氨基-3-甲基丁酸

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

线性分子式:
(CH3)2CHCH(NH2)CO2H
化学文摘社编号:
分子量:
117.15
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352209
EC Number:
211-368-9
MDL number:
Beilstein/REAXYS Number:
1721135
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


产品名称

D -缬氨酸, ≥98%

Quality Level

assay

≥98%

form

powder

optical activity

[α]23/D −32.0 to −24.0°, c = 8 in 6 M HCl

optical purity

ee: 99% (GLC)

reaction suitability

reaction type: solution phase peptide synthesis

mp

>295 °C (subl.) (lit.)

application(s)

peptide synthesis

SMILES string

CC(C)[C@@H](N)C(O)=O

InChI

1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/t4-/m1/s1

InChI key

KZSNJWFQEVHDMF-SCSAIBSYSA-N



Still not finding the right product?

Explore all of our products under D -缬氨酸


存储类别

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Kimberly A Smith et al.
American journal of respiratory cell and molecular biology, 53(3), 355-367 (2015-01-09)
Hypoxic pulmonary vasoconstriction (HPV) is an important physiological response that optimizes the ventilation/perfusion ratio. Chronic hypoxia causes vascular remodeling, which is central to the pathogenesis of hypoxia-induced pulmonary hypertension (HPH). We have previously shown that Notch3 is up-regulated in HPH
Shanshan Song et al.
American journal of physiology. Cell physiology, 307(4), C373-C383 (2014-06-13)
An increase in cytosolic Ca(2+) concentration ([Ca(2+)]cyt) in pulmonary arterial smooth muscle cells (PASMC) is a major trigger for pulmonary vasoconstriction and an important stimulus for pulmonary arterial medial hypertrophy in patients with idiopathic pulmonary arterial hypertension (IPAH). Vascular smooth
Stefan M Gysler et al.
American journal of reproductive immunology (New York, N.Y. : 1989), 73(3), 242-250 (2014-07-30)
Women with antiphospholipid syndrome (APS) are at increased risk of recurrent pregnancy loss (RPL) and preeclampsia. Antiphospholipid antibodies (aPL) directly alter trophoblast function. Treatment with low molecular weight heparin (LMWH) reduces the risk of RPL but not preeclampsia. Moreover, LMWH



全球贸易项目编号

货号GTIN
855987-25G04061833026175
855987-5G04061833026489